Literature DB >> 19909260

Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.

Angela Bithell1, Rory Johnson, Noel J Buckley.   

Abstract

HD (Huntington's disease) is a late onset heritable neurodegenerative disorder that is characterized by neuronal dysfunction and death, particularly in the cerebral cortex and medium spiny neurons of the striatum. This is followed by progressive chorea, dementia and emotional dysfunction, eventually resulting in death. HD is caused by an expanded CAG repeat in the first exon of the HD gene that results in an abnormally elongated polyQ (polyglutamine) tract in its protein product, Htt (Huntingtin). Wild-type Htt is largely cytoplasmic; however, in HD, proteolytic N-terminal fragments of Htt form insoluble deposits in both the cytoplasm and nucleus, provoking the idea that mutHtt (mutant Htt) causes transcriptional dysfunction. While a number of specific transcription factors and co-factors have been proposed as mediators of mutHtt toxicity, the causal relationship between these Htt/transcription factor interactions and HD pathology remains unknown. Previous work has highlighted REST [RE1 (repressor element 1)-silencing transcription factor] as one such transcription factor. REST is a master regulator of neuronal genes, repressing their expression. Many of its direct target genes are known or suspected to have a role in HD pathogenesis, including BDNF (brain-derived neurotrophic factor). Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD. We will describe the evidence that disruption to the REST regulon brought about by a loss of interaction between REST and mutHtt may be a key contributory factor in the widespread dysregulation of gene expression in HD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909260     DOI: 10.1042/BST0371270

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  32 in total

1.  Moving toward a gene therapy for Huntington's disease.

Authors:  J C Glorioso; J B Cohen; D L Carlisle; I Munoz-Sanjuan; R M Friedlander
Journal:  Gene Ther       Date:  2015-12       Impact factor: 5.250

2.  Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.

Authors:  S E Dougherty; J J Hollimon; L J McMeekin; A S Bohannon; A B West; M Lesort; J J Hablitz; R M Cowell
Journal:  Neurobiol Dis       Date:  2013-10-11       Impact factor: 5.996

Review 3.  The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy.

Authors:  Christopher R Sibley; Matthew J A Wood
Journal:  J Mol Med (Berl)       Date:  2011-07-13       Impact factor: 4.599

Review 4.  Prions, amyloids, and RNA: Pieces of a puzzle.

Authors:  Anton A Nizhnikov; Kirill S Antonets; Stanislav A Bondarev; Sergey G Inge-Vechtomov; Irina L Derkatch
Journal:  Prion       Date:  2016-05-03       Impact factor: 3.931

5.  MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1.

Authors:  Xiu-Li Jiang; Bo-Xiang Du; Jie Chen; Lin Liu; Wei-Bin Shao; Jie Song
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

6.  Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation.

Authors:  Sidhartha M Chafekar; Susanne Wisén; Andrea D Thompson; AnaLisa Echeverria; Gladis M Walter; Christopher G Evans; Leah N Makley; Jason E Gestwicki; Martin L Duennwald
Journal:  ACS Chem Biol       Date:  2012-06-22       Impact factor: 5.100

7.  DEFOG: discrete enrichment of functionally organized genes.

Authors:  Tobias Wittkop; Ari E Berman; K Mathew Fleisch; Sean D Mooney
Journal:  Integr Biol (Camb)       Date:  2012-06-18       Impact factor: 2.192

8.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

9.  A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing.

Authors:  Eulàlia Martí; Lorena Pantano; Mónica Bañez-Coronel; Franc Llorens; Elena Miñones-Moyano; Sílvia Porta; Lauro Sumoy; Isidre Ferrer; Xavier Estivill
Journal:  Nucleic Acids Res       Date:  2010-06-30       Impact factor: 16.971

10.  Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Authors:  Jing Jin; Jennifer Albertz; Zhihong Guo; Qi Peng; Gay Rudow; Juan C Troncoso; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2013-03-05       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.